Search

Your search keyword '"Braunwald, Eugene"' showing total 46 results

Search Constraints

Start Over You searched for: Author "Braunwald, Eugene" Remove constraint Author: "Braunwald, Eugene" Region united states Remove constraint Region: united states
46 results on '"Braunwald, Eugene"'

Search Results

1. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.

2. The evolving epidemiology of acute coronary syndromes.

3. Loop Diuretics in Acute Decompensated Heart Failure: Necessary? Evil? A Necessary Evil?

4. Redefining medical treatment in the management of unstable angina.

5. The Evidence Supporting Cardiovascular Guidelines: Is There Evidence of Progress in the Last Decade?

6. Subspecialists and internal medicine: a perspective.

7. Hospitalizations for Heart Failure in the United States--A Sign of Hope.

8. Reconsidering the Role for Digoxin in the Management of Acute Heart Failure Syndromes.

9. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial.

10. New Horizons in Cardioprotection Recommendations From the 2010 National Heart, Lung, and Blood Institute Workshop.

11. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial.

12. A Comparison of Management Patterns after Acute Myocardial Infarction in Canada and the United States.

13. Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy.

14. Transmethylamine-N-Oxide Is Associated With Diffuse Cardiac Fibrosis in People Living With HIV.

15. Left atrial structure and function and the risk of death or heart failure in atrial fibrillation.

16. Baseline Characteristics of the VANISH Cohort.

17. Diabetes, heart failure, and renal dysfunction: The vicious circles.

18. Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48.

19. Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial).

20. Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial.

21. Efficacy and safety of vorapaxar as approved for clinical use in the United States.

23. Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial.

24. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease.

25. American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38).

26. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study.

27. Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies.

28. New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop.

29. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22.

30. National Heart, Lung, and Blood Institute working group on emergency department management of acute heart failure: research challenges and opportunities.

33. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38.

34. The year in non-ST-segment elevation acute coronary syndrome.

35. Thrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and heart failure in patients with ST-elevation myocardial infarction in the TIMI 2 clinical trial.

36. 2007 update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: implications for emergency department practice.

37. The American Society for Clinical Investigation, 1952--1975: a personal perspective.

39. Departments, divisions and centers in the evolution of medical schools.

40. Application of the Thrombolysis in Myocardial Infarction risk index in non-ST-segment elevation myocardial infarction: evaluation of patients in the National Registry of Myocardial Infarction.

41. Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction.

42. Evaluation of the association of proximal coronary culprit artery lesion location with clinical outcomes in acute myocardial infarction.

44. Collaborating with industry--choices for the academic medical center.

45. Prognosis in the thrombolysis in myocardial ischemia III registry according to the Braunwald unstable angina pectoris classification.

46. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors.

Catalog

Books, media, physical & digital resources